Pegcetacoplan

Phase 3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

PNH

Conditions

PNH

Trial Timeline

Aug 27, 2018 → Jun 1, 2025

NCT ID

NCT03531255

About Pegcetacoplan

Pegcetacoplan is a phase 3 stage product being developed by Apellis Pharmaceuticals for PNH. The current trial status is active. This product is registered under clinical trial identifier NCT03531255. Target conditions include PNH.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04729062	Pre-clinical	Completed	—	—	C3G
NCT07020832	Phase 3	Recruiting	Feb 1, 2026	Aug 1, 2028	Delayed Graft Function
NCT06161584	Pre-clinical	Active	Sep 28, 2023	Jun 1, 2027	Geographic Atrophy
NCT05809531	Phase 3	Active	May 29, 2023	Jul 1, 2027	C3G
NCT05067127	Phase 3	Completed	Nov 12, 2021	Jan 14, 2025	C3G
NCT04572854	Phase 2	Active	Sep 7, 2021	Jan 1, 2026	C3G
NCT04901936	Phase 2	Recruiting	Feb 4, 2021	Dec 1, 2028	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03531255	Phase 3	Active	Aug 27, 2018	Jun 1, 2025	PNH
NCT03593200	Phase 2	Completed	Aug 16, 2018	Oct 22, 2019	PNH
NCT03465709	Phase 1/2	Terminated	Feb 14, 2018	Apr 5, 2019	Neovascular Age-related Macular Degeneration
NCT02588833	Phase 1	Completed	Dec 1, 2015	Aug 26, 2019	Paroxysmal Nocturnal Hemoglobinuria
NCT02503332	Phase 2	Completed	Sep 24, 2015	Jan 17, 2018	Geographic Atrophy
NCT02264639	Phase 1	Completed	Feb 23, 2015	Oct 22, 2018	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02461771	Phase 1	Completed	Jan 28, 2015	Mar 8, 2016	Neovascular Age-Related Macular Degeneration

Competing Products

20 competing products in PNH

See all competitors

Product	Company	Stage	Hype Score
Iptacopan (LNP023)	Novartis	Phase 3	77
iptacopan	Novartis	Phase 2	52
LNP023 + Eculizumab + Ravulizumab	Novartis	Phase 3	77
LNP023	Novartis	Phase 3	77
REGN3918	Regeneron Pharmaceuticals	Phase 2	51
ALN-CFB + Placebo	Regeneron Pharmaceuticals	Phase 1/2	40
HSK39297 tablets + Eculizumab Injection	Haisco Pharmaceutical Group	Phase 3	74
HSK39297 tablets + HSK39297 tablets + HSK39297 tablets	Haisco Pharmaceutical Group	Phase 1	30
HSK39297 tablets	Haisco Pharmaceutical Group	Phase 3	74
Carbon-14 labeled HSK39297	Haisco Pharmaceutical Group	Phase 1	30
HSK39297	Haisco Pharmaceutical Group	Phase 2	49
Zilucoplan (RA101495)	UCB	Phase 2	49
Zilucoplan (RA101495)	UCB	Phase 2	49
Zilucoplan (RA101495)	UCB	Phase 2	49
ALN-CC5 + Sterile Normal Saline (0.9% NaCl)	Alnylam Pharmaceuticals	Phase 1/2	38
Placebo + BCX9930 monotherapy	BioCryst Pharmaceuticals	Phase 2	47
Eculizumab + Ravulizumab + BCX9930	BioCryst Pharmaceuticals	Phase 2	47
Pegcetacoplan	Apellis Pharmaceuticals	Phase 2	47
Pegcetacoplan	Apellis Pharmaceuticals	Phase 2	47
Pegcetacoplan	Apellis Pharmaceuticals	Phase 1	28

Other Products from Apellis Pharmaceuticals

PegcetacoplanPhase 3

APL-2 + APL-2Phase 3

APL-2, PegcetacoplanPhase 3

APL-2Phase 3

PegcetacoplanPhase 3